News
Hosted on MSN5mon
Sonnet BioTherapeutics to expand trial of SON-1010 with ... - MSNUS-based biotechnology company Sonnet BioTherapeutics has expanded its Phase I SB101 study of SON-1010 for advanced solid tumours. The company is adding a cohort to assess the efficacy of SON-1010 ...
PRINCETON, NJ/ ACCESSWIRE/ April 13, 2022/ Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback